Member

Zymeron


Zymeron is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative healthcare technologies that deliver step-change performance. The company focuses on proactive health solutions to address critical unmet needs in the pharmaceutical sciences, particularly in drug delivery and formulation technologies.

Industries

biotechnology
health-care
health-diagnostics
nanotechnology
product-research

Nr. of Employees

small (1-50)

Zymeron

400 Park Offices Drive, STE 211 PO Box 12072 Research Triangle Park, NC 27709


Patents

Immunoassay platform for the serological discrimination of closely related viruses

2025-01-14 • US-12196755-B2

View Details

Products

Bone marrow-targeted myeloprotective therapeutic (preclinical)

Preclinical injectable drug program that delivers cytoprotective molecules to hematopoietic stem and progenitor cells to prevent chemotherapy- or radiation-induced myelosuppression.

Rapid lab-on-chip sterility testing system (rapid microbiological method)

Automated, closed-system lab-on-chip sterility test providing qualitative presence/absence results in under 30 minutes with single-cell sensitivity and non-destructive sample handling.

Long-acting subcutaneous prophylactic drug implant (preclinical)

Biodegradable subcutaneous implant technology intended to provide customizable-duration prophylaxis (1–12 months) for infectious disease prevention without requiring surgical removal.

Dual biologic–small molecule wound therapeutics

Extracellular vesicle-based wound therapy program for biofilm management, antimicrobial activity, and wound healing promotion, developed with companion diagnostic and sterility testing components.

Expertise Areas

  • Myeloprotection and chemoprotection
  • Bone marrow-targeted drug delivery
  • Injectable formulation and reformulation
  • Long-acting implantable drug delivery
  • Show More (6)

Key Technologies

  • Peptide drug conjugates for targeted delivery
  • Extracellular vesicle-mediated delivery
  • Lab-on-chip microfluidics
  • Miniaturized automated instrumentation
  • Show More (6)

Key People

Not specified

Not specified


News & Updates

Zymeron Corporation announced that its myelotoxicity drug program is boosted by a $3.0M federal funding to advance its lead drug candidate in preclinical studies.

Zymeron Corporation announced that it received multi-year funding from the Department of Defense to continue its development of a long-lasting antimalaria prophylactic drug.

Zymeron Corporation announced that it has relocated to the Frontier Campus Building 400, Research Triangle Park, NC, providing renovated dynamic laboratory spaces for startups.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.